UNSPSC 51102863: Neomycin/polymyxin b

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE109. This VA Drug Class (DE109) classifies this compound as belonging to the group ANTI-INFECTIVE, TOPICAL, OTHER.

UNSPSC 51102863 Neomycin/polymyxin b, a Commodity code, shows minimal recent activity aligned with its nominal scope. State and local governments use this code to procure pharmaceutical products, but the recent opportunities in the dataset involve unrelated medications — doxycycline, ciprofloxacin, and naloxone — suggesting either misclassification at posting or inconsistent code application across jurisdictions. When state and local agencies do solicit under pharmaceutical-product codes, they typically source through cooperative purchasing vehicles such as MMCAP Infuse or directly via invitation for bid, with issuing bodies ranging from state health departments to county health authorities.

Recent activity appears concentrated in Florida and Illinois. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026, through the MMCAP Infuse consortium for $2,999,999.11 over the three-year contract term (12-month initial plus two optional one-year renewals), covering doxycycline and ciprofloxacin supplies under an IFB process. Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, though the notice displays a response date of July 26, 2023, indicating a data-quality issue. Neither opportunity explicitly required set-asides or domestic-product preferences. The code shows no current open solicitations matching the neomycin/polymyxin b description; activity under this code warrants direct monitoring of state health department RFPs and cooperative purchasing vehicle addenda.